Topiramate in Migraine Prevention: A Double‐Blind, Placebo‐Controlled Study

Storey, James R.; Calder, Christopher; Hart, David; Potter, D

doi:10.1046/j.1526-4610.2001.01190.x

Cited by 162 publications

(115 citation statements)

References 20 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…When prescribing topiramate, clinicians need to be familiar with its AEs and titrate the drug appropriately. Topiramate may take weeks or months to become effective, and the recommended titration is 25 mg per week to an initial starting dose of 100 mg [2]. This is in contrast to its use in epilepsy which suggests a 50 mg/week titration up to a minimum of 200 mg/day [45].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety of topiramate for treating migraines

Marmura

2014

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Topiramate is approved by the Food and Drug Administration (FDA) for the prevention of migraine in adults [1,2]and adolescents [3,4]. The usual dose of topiramate for migraine is 100 mg, because this dose has the best balance of efficacy and low adverse events (AEs) [5].…”

mentioning

confidence: 99%

Safety of topiramate for treating migraines

Marmura

2014

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

“…Среди побочных эффектов наиболее часто имеют место снижение внимания и памяти (12,5%), снижение веса (5,6%), сенсорные изменения (2,8%) [14][15][16].…”

Section: профилактическая терапия мигрениunclassified

Migraine and Tension-Type Headache in Children: The Approach to Effective Treatment. Part 2

Sergeev¹

2012

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Доказательная база по эффективности и безопас-ности фармакотерапии головных болей (ГБ) у детей огра-ничена. Детским неврологам приходится использовать неодобренные для применения в педиатрической прак-тике лекарственные средства, индивидуально взвеши-вая возможную пользу и риск развития нежелательных лекарственных реакций. Отсутствие в России четких рекомендаций по симптоматической и профилактиче-ской терапии первичных ГБ в детском возрасте зача-стую приводит к назначению неэффективной (Но-шпа, ноотропы, «сосудистые» препараты, гомеопатические средства) и небезопасной (купирование эпизодов ГБ комбинированными анальгетиками, содержащими метамизол натрия, кодеин или фенобарбитал) терапии. Нередкое следствие таких назначений -ухудшение течения мигрени и головной боли напряжения (ГБН) с формированием хронической ежедневной головной боли, лекарственно-индуцированной головной боли и развитием серьезных нежелательных лекарственных реакций (НЛР).Фармакотерапию мигрени и ГБН подразделяют на симптоматическую (эпизодический прием препарата с целью купирования приступа боли) и профилактическую (регулярная, длительная терапия, направленная на сни-жение частоты и интенсивности болевых приступов). ФАРМАКОТЕРАПИЯ МИГРЕНИСимптоматическая терапия мигрени Целью симптоматической терапии служит быстрое и эффективное купирование приступа ГБ с полной нор-мализацией повседневной активности ребенка и отсут-ствием рецидива болевого синдрома.Основными принципами симптоматического лече-ния приступа мигрени у детей являются следующие:

show abstract

“…Adult trials were recently reported using topiramate at doses of 200 mg/day (divided bid) and demonstrated a 50% reduction in headache frequency and severity. 25 One retrospective study assessing the efficacy of topiramate for pediatric headache included 75 patients of whom 41 were available for follow-up visits. Daily doses of 1.4 (ϩ/Ϫ 0.74) mg/kg/day were reached and headache frequency was reduced from 16.5 (ϩ/Ϫ 10) headaches/ month to 11.6 (ϩ/Ϫ 10) headaches/month (pϽ0.001).…”

Section: Anti-epileptic Agentsmentioning

confidence: 99%

The pharmacological treatment options for pediatric migraine: An evidence-based appraisal

Lewis

Winner

2006

NeuroRX

View full text Add to dashboard Cite

Summary:The treatment of children and adolescents who suffer from migraine headaches must be individually tailored, flexible, and balanced with a blend of bio-behavioral measures, agents for acute treatment and, if needed, daily preventive medicines. While controlled data is limited, there is now enough evidence available to provide a rational framework to build treatment plans appropriate for the pediatric population. Essentially, the pharmacological management of pediatric migraine divides into agents for the acute attacks and agents used daily to prevent or reduce the frequency of attacks. For the acute treatment, the most rigorously studied agents are ibuprofen, acetaminophen, and the nasal spray forms of sumatriptan and zolmitriptan, all of which have shown both safety and efficacy in controlled trials. For preventive treatment the calcium channel blocker flunarezine has the best efficacy profile in controlled trials, but is not available in the U.S. A growing body of data, mostly uncontrolled, is emerging regarding the use of several anti-epileptic agents (e.g. topiramate, disodium valproate, levateracetam), as well as the antihistamine cyproheptadine and the anti-depressant amitriptyline.

show abstract

Topiramate in Migraine Prevention: A Double‐Blind, Placebo‐Controlled Study

Abstract: Preventative therapy with topiramate significantly reduced migraine frequency. Larger multicenter clinical studies may further delineate the role of topiramate in migraine prevention.

Cited by 162 publications

References 20 publications

Safety of topiramate for treating migraines

Safety of topiramate for treating migraines

Migraine and Tension-Type Headache in Children: The Approach to Effective Treatment. Part 2

The pharmacological treatment options for pediatric migraine: An evidence-based appraisal

Contact Info

Product

Resources

About